Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities
- PMID: 2836250
- DOI: 10.2337/diab.37.3.359
Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities
Abstract
The plasma and tissue concentration of ascorbic acid (AA) is reduced in diabetes. This study was designed to investigate the mechanism and significance of this phenomenon. The low plasma AA concentration of diabetic rats can be normalized by dietary AA supplement (20-40 mg/day), a dosage approximately equal to the maximal synthetic rate of this substance in the rats. Treatment of diabetic rats with this regime prevented the decrease in activity of granulation tissue prolyl hydroxylase (PRLase), an AA-dependent enzyme required for maintaining the normal properties of collagen. The decreased plasma AA concentration and granulation tissue PRLase activity in diabetes can also be normalized by the aldose reductase inhibitor tolrestat. We conclude that in diabetic animals there is a true deficiency of AA that may be responsible for some of the changes of collagen observed in diabetes. Treatment with AA or an aldose reductase inhibitor may prevent some of the diabetic complications with underlying collagen abnormalities.
Similar articles
-
Ascorbic acid metabolism and polyol pathway in diabetes.Diabetes. 1989 Feb;38(2):257-61. doi: 10.2337/diab.38.2.257. Diabetes. 1989. PMID: 2492477
-
Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.Proc Soc Exp Biol Med. 1986 Sep;182(4):505-10. doi: 10.3181/00379727-182-42372. Proc Soc Exp Biol Med. 1986. PMID: 3090558
-
Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat.J Diabet Complications. 1988 Jan-Mar;2(1):16-8. doi: 10.1016/0891-6632(88)90020-7. J Diabet Complications. 1988. PMID: 2968349
-
Potential use of aldose reductase inhibitors to prevent diabetic complications.Clin Pharm. 1990 Jun;9(6):446-57. Clin Pharm. 1990. PMID: 2114249 Review.
-
[Regulation of chronic proliferative inflammation by anti-inflammatory drugs (author's transl)].Yakugaku Zasshi. 1982 Mar;102(3):221-35. doi: 10.1248/yakushi1947.102.3_221. Yakugaku Zasshi. 1982. PMID: 6286919 Review. Japanese. No abstract available.
Cited by
-
Role of bioactive food components in diabetes prevention: effects on Beta-cell function and preservation.Nutr Metab Insights. 2014 Jul 6;7:51-9. doi: 10.4137/NMI.S13589. eCollection 2014. Nutr Metab Insights. 2014. PMID: 25092987 Free PMC article. Review.
-
Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation.Diabetologia. 1991 Mar;34(3):171-5. doi: 10.1007/BF00418271. Diabetologia. 1991. PMID: 1884888
-
Altered sialin mRNA gene expression in type 2 diabetic male Wistar rats: implications for nitric oxide deficiency.Sci Rep. 2023 Mar 10;13(1):4013. doi: 10.1038/s41598-023-31240-4. Sci Rep. 2023. PMID: 36899088 Free PMC article.
-
Whole-food phytochemicals antioxidative potential in alloxan-diabetic rats.Toxicol Rep. 2018 Jan 12;5:240-250. doi: 10.1016/j.toxrep.2018.01.002. eCollection 2018. Toxicol Rep. 2018. PMID: 29854595 Free PMC article.
-
Effect of N-acetyl cysteine in prevention of contrast nephropathy on patients under intravenous pyelography and contrast CT.Adv Biomed Res. 2012;1:28. doi: 10.4103/2277-9175.98153. Epub 2012 Jul 6. Adv Biomed Res. 2012. PMID: 23210087 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources